Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region

Abstract:: Objectives: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. Methods: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse tra...

Full description

Bibliographic Details
Main Authors: Robert Markewitz, MD, Antje Torge, PhD, Klaus-Peter Wandinger, MD, Daniela Pauli, MD, Justina Dargvainiene, Andre Franke, MD, Luis Bujanda, MD, PhD, José Maria Marimón, PharmD, Jesus M. Banales, PhD, María A. Gutierrez-Stampa, MD, PhD, Beatriz Nafría, BSc, Ralf Junker, MD
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:International Journal of Infectious Diseases
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221005701
id doaj-d19d07a29ca649b6aa785dc6db12940e
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Robert Markewitz, MD
Antje Torge, PhD
Klaus-Peter Wandinger, MD
Daniela Pauli, MD
Justina Dargvainiene
Andre Franke, MD
Luis Bujanda, MD, PhD
José Maria Marimón, PharmD
Jesus M. Banales, PhD
María A. Gutierrez-Stampa, MD, PhD
Beatriz Nafría, BSc
Ralf Junker, MD
spellingShingle Robert Markewitz, MD
Antje Torge, PhD
Klaus-Peter Wandinger, MD
Daniela Pauli, MD
Justina Dargvainiene
Andre Franke, MD
Luis Bujanda, MD, PhD
José Maria Marimón, PharmD
Jesus M. Banales, PhD
María A. Gutierrez-Stampa, MD, PhD
Beatriz Nafría, BSc
Ralf Junker, MD
Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
International Journal of Infectious Diseases
SARS-CoV-2
COVID-19
RT-qPCR
Ct value
anti-SARS-CoV-2 antibodies
author_facet Robert Markewitz, MD
Antje Torge, PhD
Klaus-Peter Wandinger, MD
Daniela Pauli, MD
Justina Dargvainiene
Andre Franke, MD
Luis Bujanda, MD, PhD
José Maria Marimón, PharmD
Jesus M. Banales, PhD
María A. Gutierrez-Stampa, MD, PhD
Beatriz Nafría, BSc
Ralf Junker, MD
author_sort Robert Markewitz, MD
title Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
title_short Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
title_full Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
title_fullStr Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
title_full_unstemmed Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
title_sort analysis of sars-cov-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-sars-cov-2 antibodies from a high incidence region
publisher Elsevier
series International Journal of Infectious Diseases
issn 1201-9712
publishDate 2021-09-01
description Abstract:: Objectives: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. Methods: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse transcription-quantitative polymerase chain reaction) on admission were compared between 2 assays and correlated with the antibody response (in the course of the disease), the clinical course and the time since onset of symptoms. Results: Ct values for 2 of 3 target genes showed significant differences between the 2 assays used (P=0.012 and P<0.0001). Ct values were significantly higher for antibody positive patients (P<0.0001) and positively correlated with the amount of time since onset of symptoms (R: 0.332–0.363; P<0.001). Patients with fatal outcomes showed higher viral loads than survivors (P<0.0001). Conclusions: Ct values depend strongly on assay used and target gene examined and should not be used as quantitative values to guide therapeutic or diagnostic decisions. The inverse association between antibody status and viral load suggests that antibodies contribute to the elimination of the virus, independent of the outcome, which is influenced by the viral load on admission and might depend more strongly on other parts of the immune response.
topic SARS-CoV-2
COVID-19
RT-qPCR
Ct value
anti-SARS-CoV-2 antibodies
url http://www.sciencedirect.com/science/article/pii/S1201971221005701
work_keys_str_mv AT robertmarkewitzmd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT antjetorgephd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT klauspeterwandingermd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT danielapaulimd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT justinadargvainiene analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT andrefrankemd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT luisbujandamdphd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT josemariamarimonpharmd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT jesusmbanalesphd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT mariaagutierrezstampamdphd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT beatriznafriabsc analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT ralfjunkermd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
_version_ 1717369188962533376
spelling doaj-d19d07a29ca649b6aa785dc6db12940e2021-09-25T05:05:25ZengElsevierInternational Journal of Infectious Diseases1201-97122021-09-01110114122Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence regionRobert Markewitz, MD0Antje Torge, PhD1Klaus-Peter Wandinger, MD2Daniela Pauli, MD3Justina Dargvainiene4Andre Franke, MD5Luis Bujanda, MD, PhD6José Maria Marimón, PharmD7Jesus M. Banales, PhD8María A. Gutierrez-Stampa, MD, PhD9Beatriz Nafría, BSc10Ralf Junker, MD11Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, Germany; Corresponding author: Robert Markewitz, MD, Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Ratzeburger Alle 160, 23560 Lübeck, Germany. Tel.: +49 451/50016315.Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, GermanyInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, GermanyInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, GermanyInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, GermanyInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel &amp; University Hospital Schleswig-Holstein, Kiel, GermanyDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital, San Sebastián, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, “Instituto de Salud Carlos III”), University of the Basque Country (UPV/EHU), San Sebastián, SpainBiodonostia Health Research Institute, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group, Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Microbiology Department, San Sebastián, SpainDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital, San Sebastián, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, “Instituto de Salud Carlos III”), University of the Basque Country (UPV/EHU), San Sebastián, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, SpainOsakidetza, OSI Donostialdea, Altza Primary Care; Biodonostia Health Research Institute, San Sebastián, SpainClinical Biochemistry Department, Biodonostia Health Research Institute Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation. San Sebastián, SpainInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, GermanyAbstract:: Objectives: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. Methods: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse transcription-quantitative polymerase chain reaction) on admission were compared between 2 assays and correlated with the antibody response (in the course of the disease), the clinical course and the time since onset of symptoms. Results: Ct values for 2 of 3 target genes showed significant differences between the 2 assays used (P=0.012 and P<0.0001). Ct values were significantly higher for antibody positive patients (P<0.0001) and positively correlated with the amount of time since onset of symptoms (R: 0.332–0.363; P<0.001). Patients with fatal outcomes showed higher viral loads than survivors (P<0.0001). Conclusions: Ct values depend strongly on assay used and target gene examined and should not be used as quantitative values to guide therapeutic or diagnostic decisions. The inverse association between antibody status and viral load suggests that antibodies contribute to the elimination of the virus, independent of the outcome, which is influenced by the viral load on admission and might depend more strongly on other parts of the immune response.http://www.sciencedirect.com/science/article/pii/S1201971221005701SARS-CoV-2COVID-19RT-qPCRCt valueanti-SARS-CoV-2 antibodies